Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
Scinai Immunotherapeutics (Nasdaq: SCNI) published its Q2 2024 financial results and provided a business update. Key highlights include:
1. Restructuring of a €26.6 million (~$29 million) EIB loan into equity, expected to close by August 23, 2024, to regain Nasdaq compliance.
2. CDMO business unit received work orders valued at ~$600K since January 2024, maintaining 2024 revenue guidance of $1.25 million.
3. Promising results from in-vivo proof of concept study for NanoAb in psoriasis treatment.
4. Positive regulatory feedback from PEI for Phase 1/2a clinical trial of anti-IL-17A/F nanoAb in Plaque Psoriasis.
5. Q2 2024 financial results: R&D expenses decreased to $2.79 million, net loss reduced to $4.48 million, and cash position of $3.08 million as of June 30, 2024.
Scinai Immunotherapeutics (Nasdaq: SCNI) ha pubblicato i risultati finanziari del secondo trimestre 2024 e fornito un aggiornamento aziendale. I punti chiave includono:
1. Ristrutturazione di un prestito EIB di 26,6 milioni di euro (~29 milioni di dollari) in capitale, previsto in chiusura entro il 23 agosto 2024, per riacquistare la conformità con il Nasdaq.
2. L'unità commerciale CDMO ha ricevuto ordini di lavoro per un valore di ~600K dollari da gennaio 2024, mantenendo la guida dei ricavi per il 2024 fissata a 1,25 milioni di dollari.
3. Risultati promettenti dallo studio di prova di concetto in vivo per il NanoAb nel trattamento della psoriasi.
4. Feedback regolatorio positivo dal PEI per la sperimentazione clinica di fase 1/2a dell'anti-IL-17A/F nanoAb nella psoriasi a placche.
5. Risultati finanziari del secondo trimestre 2024: le spese per R&S sono scese a 2,79 milioni di dollari, la perdita netta è stata ridotta a 4,48 milioni di dollari, e la posizione di liquidità è di 3,08 milioni di dollari al 30 giugno 2024.
Scinai Immunotherapeutics (Nasdaq: SCNI) publicó sus resultados financieros del segundo trimestre de 2024 y proporcionó una actualización empresarial. Los aspectos más destacados incluyen:
1. Reestructuración de un préstamo de 26,6 millones de euros (~29 millones de dólares) del BEI en capital, que se espera cierre para el 23 de agosto de 2024, para recuperar el cumplimiento con Nasdaq.
2. La unidad de negocio CDMO recibió órdenes de trabajo valoradas en ~600K dólares desde enero de 2024, manteniendo la proyección de ingresos de 1,25 millones de dólares para 2024.
3. Resultados prometedores de un estudio de prueba de concepto in vivo para NanoAb en el tratamiento de la psoriasis.
4. Comentarios regulatorios positivos del PEI para el ensayo clínico de fase 1/2a del anti-IL-17A/F nanoAb en Psoriasis en placa.
5. Resultados financieros del segundo trimestre de 2024: los gastos en I+D disminuyeron a 2,79 millones de dólares, la pérdida neta se redujo a 4,48 millones de dólares, y la posición de efectivo es de 3,08 millones de dólares al 30 de junio de 2024.
Scinai Immunotherapeutics (Nasdaq: SCNI)는 2024년 2분기 재무 결과를 발표하고 사업 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
1. 유럽투자은행(EIB)의 2,660만 유로 (~2,900만 달러) 대출을 자본으로 재구성하며, 2024년 8월 23일까지 마무리할 예정으로 Nasdaq 준수를 회복합니다.
2. CDMO 사업 부문은 2024년 1월 이후 600K 달러 상당의 작업 주문을 수주하여 2024년 매출 지침 125만 달러를 유지합니다.
3. 건선 치료를 위한 NanoAb의 인 비보 개념 증명 연구에서 유망한 결과가 나왔습니다.
4. 판상 건선에서 anti-IL-17A/F nanoAb의 1상/2a 임상 시험에 대해 PEI로부터 긍정적인 규제 피드백을 받았습니다.
5. 2024년 2분기 재무 결과: 연구개발비는 279만 달러로 감소하고 순손실은 448만 달러로 줄었으며, 2024년 6월 30일 기준 현금 보유액은 308만 달러입니다.
Scinai Immunotherapeutics (Nasdaq: SCNI) a publié ses résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour sur ses activités. Les points clés comprennent:
1. Restructuration d'un prêt de 26,6 millions d'euros (~29 millions de dollars) de la BEI en capitaux propres, qui devrait être finalisée d'ici le 23 août 2024, pour retrouver la conformité avec le Nasdaq.
2. L'unité commerciale CDMO a reçu des commandes de travail d'une valeur d'environ 600K dollars depuis janvier 2024, maintenant la prévision de revenus pour 2024 à 1,25 million de dollars.
3. Résultats prometteurs d'une étude de preuve de concept in vivo pour NanoAb dans le traitement du psoriasis.
4. Retours positifs des régulateurs du PEI pour l'essai clinique de phase 1/2a de l'anti-IL-17A/F nanoAb dans le psoriasis en plaques.
5. Résultats financiers du deuxième trimestre 2024 : les dépenses de R&D ont diminué à 2,79 millions de dollars, la perte nette a été réduite à 4,48 millions de dollars et la position de liquidités s'élevait à 3,08 millions de dollars au 30 juin 2024.
Scinai Immunotherapeutics (Nasdaq: SCNI) hat die Finanzergebnisse für das zweite Quartal 2024 veröffentlicht und ein Update zum Geschäft bereitgestellt. Wichtige Highlights beinhalten:
1. Umstrukturierung eines EIB-Darlehens in Höhe von 26,6 Millionen Euro (~29 Millionen Dollar) in Eigenkapital, das voraussichtlich bis zum 23. August 2024 abgeschlossen wird, um die Nasdaq-Konformität wiederherzustellen.
2. Die CDMO-Geschäftseinheit erhielt seit Januar 2024 Arbeitsaufträge im Wert von ~600K Dollar und hält die Umsatzprognose von 1,25 Millionen Dollar für 2024 aufrecht.
3. Vielversprechende Ergebnisse aus einer in-vivo Machbarkeitsstudie für NanoAb zur Behandlung von Psoriasis.
4. Positives regulatorisches Feedback vom PEI für die Phase 1/2a klinische Studie von anti-IL-17A/F nanoAb bei Plaque-Psoriasis.
5. Finanzielle Ergebnisse für das zweite Quartal 2024: Die F&E-Ausgaben sind auf 2,79 Millionen Dollar gesunken, der Nettoverlust wurde auf 4,48 Millionen Dollar gesenkt und die Liquiditätsposition betrug am 30. Juni 2024 3,08 Millionen Dollar.
- Restructuring of €26.6 million EIB loan to equity, potentially regaining Nasdaq compliance
- CDMO business unit received work orders valued at ~$600K since January 2024
- Maintaining 2024 revenue guidance of $1.25 million for CDMO services
- Promising results from in-vivo proof of concept study for NanoAb in psoriasis treatment
- Positive regulatory feedback from PEI for Phase 1/2a clinical trial of anti-IL-17A/F nanoAb
- Reduced net loss to $4.48 million in Q2 2024 compared to $7.28 million in Q2 2023
- Gross loss of $164,000 reported for Q2 2024
- Cash and cash equivalents decreased to $3.08 million as of June 30, 2024, from $4.87 million as of December 31, 2023
- Shareholders' deficit increased to $7.28 million as of June 30, 2024, from $4.57 million as of December 31, 2023
Insights
The restructuring of $29 million in debt to equity is a significant positive development for Scinai. This move will substantially improve the company's balance sheet, potentially regaining Nasdaq compliance by August 23. The reduction in R&D and marketing expenses shows effective cost management, contributing to a narrower net loss of $4.48 million compared to $7.28 million in the same period last year.
However, the gross loss of $164,000 on $284,000 revenue is concerning, indicating challenges in the CDMO business unit's profitability. The cash position of $3.08 million is relatively low, which may necessitate additional funding in the near future. The company's guidance of $1.25 million in expected revenues for 2024 seems optimistic given the current run rate, but could be achievable if CDMO contracts materialize as anticipated.
Scinai's progress in its NanoAb platform is promising, particularly the positive results from the in-vivo proof of concept study for psoriasis treatment. The favorable feedback from the Paul Erlich Institute for the Phase 1/2a clinical trial design is a significant regulatory milestone, potentially accelerating the development timeline and reducing costs.
The company's strategy to focus on mild to moderate plaque psoriasis with an intralesional injection could differentiate it in a crowded market. However, with the Phase 1/2a study not expected to commence until the second half of 2025, Scinai faces a long road to market. The pursuit of strategic partnerships for both the COVID-19 and psoriasis programs could provide much-needed resources and validation, but concrete deals are yet to materialize.
Scinai's pivot to CDMO services shows promise, with $600K in work orders since January and ongoing contract discussions. The growing demand for boutique CDMO services from early-stage biotech companies could provide a stable revenue stream. However, the company's current revenue of $284,000 for H1 2024 suggests a significant ramp-up is needed to meet the $1.25 million guidance for the year.
The company's marketing efforts, including participation in major pharmaceutical conferences, could help build brand awareness. The unique aseptic processing course held at their facility demonstrates initiative in establishing industry connections. While these efforts are positive, investors should closely monitor the conversion of these activities into concrete revenue growth in the coming quarters to validate the CDMO strategy.
JERUSALEM , Aug. 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the quarter ended June 30, 2024 and provided a business update. The Company will hold a webinar covering its Q2 2024 financial results and business update on August 20th at 11AM EDT/18:00
Business Update & Recent Highlights
Conversion of EIB Loan into Equity and Regaining Nasdaq Compliance
On June 7, 2024, the Company announced that on June 5, 2024, it had received formal notification from the Listing Qualification Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") that the Company remains non-compliant with the requirement in Listing Rule 5550(b)(1) that a company have stockholders' equity of at least
On July 3, 2024, the Company announced that the Hearings Panel had determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before August 14, 2024 a public disclosure demonstrating compliance with the Equity Requirement.
On August 13, 2024, the Company announced that it had signed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract with the EIB. The closing of the transaction is subject to delivery of customary closing documents and is expected to close by August 23, 2024. In connection with the transaction, an amount equal to approximately
On August 14, 2024h the Company received from the Nasdaq Hearing Panel an extension until August 23, 2024 to close the restructuring transaction with the EIB and thereby demonstrate compliance with the Equity Requirement. Following closing of the restructuring transaction with the EIB, the Company intends to issue a press release submitted on Form 6-K stating that as a result of the completed loan restructuring, the Company has stockholders' equity above
CDMO business unit
Since Jan 2024, the Company has received CDMO work orders valued at approximately
In addition, in 2024 the Company has been pursuing extensive targeted marketing activities, including online advertisements, direct outreach campaigns and participation in major pharmaceutical conferences, such as BIO Europe Spring in
The Company's CDMO unit is currently focused both on executing drug development projects for its clients and on validating its processes and facilities to be ready for cGMP inspection by the Israeli Ministry of Health.
In June 2024, the Company held its first of its kind, hands on aseptic processing course at its facility in
Pipeline Development
The Company is aggressively advancing the NanoAb preclinical development. At the end of April 2024, the Company concluded an in-vivo proof of concept animal study in collaboration with Prof. Amos Gilhar, a world-renowned dermatologist of the prestigious Technion Israel Institute of Technology.
On July 15, 2024, the Company announced promising results as the statistical analysis of psoriasis markers measured in the study confirmed that the effect of Scinai's NanoAb was similar to that of the two comparator drugs, supporting the hypothesis that intralesional injection of a nanoAb blocking the IL-17 cytokine can positively impact the inflammatory cytokine cascade, and lead to reduction in psoriatic lesion severity and improvement of the skin's integrity. By delivering a biological treatment directly into psoriatic lesions, the Company aims to improve disease management for patients suffering from mild to moderate plaque psoriasis by offering the high potency and specificity advantages reserved for biologic drugs while providing a safer and more convenient treatment option compared to existing therapies currently offered to this patient category.
On June 4, 2024, the Company met for a scientific advisory meeting with the Paul Erlich Institute (the PEI) of
Consequently, on July 23, 2024, the Company announced the receipt of positive regulatory feedback from the PEI for its drug development program towards Phase 1/2a clinical trial of its anti-IL-17A/F nanoAb (SCN-1) in Plaque Psoriasis. The minutes of meeting clarified its preclinical toxicology and clinical program for Plaque Psoriasis with intralesional injections for the treatment of patients with mild to moderate Plaque Psoriasis. The PEI requested to see data of efficacy in blocking IL-17F, and this data became available as per the Company's announcement on July 15, 2024 describing the positive in vivo proof of concept results. The PEI accepted the Company's position that toxicology studies can be conducted in pigs rather than in Non-Human Primates. The PEI also accepted the Company's position to compare the SCN-1 to placebo directly in patients with mild to moderate plaque psoriasis while skipping the need for testing in healthy volunteers, resulting in a phase 1/2a clinical trial, which will assess both safety and efficacy in the same trial. Moreover, the PEI agreed to compare SCN-1 to placebo on the same human subject, a strategy that could significantly reduce the number of patients required for the clinical trial. Last, the PEI commented that the manufacturing process looks well developed and that controls and specifications presented are acceptable.
The Phase 1/2a study is expected to include approximately 24 plaque psoriasis patients and is expected to commence in the second half of 2025 with readout in 2026.
Additional NanoAbs for treatment of additional autoimmune diseases, such as asthma, atopic dermatitis and wet AMD, have been discovered and characterized at Max Planck and University Medical Center Göttingen as part of their research collaboration agreement with Scinai. Scinai holds exclusive options for exclusive licenses at pre-agreed financial terms for each of the resulting NanoAbs.
The Company is pursuing strategic partnerships and sublicensing options for both its COVID-19 self-administered inhaled NanoAb, which demonstrated highly promising in vivo results in animals as both a therapeutic and prophylactic treatment, and its anti-IL-17 nanoAb for the treatment of plaque psoriasis and other potential indications.
Q2 2024 Financial Summary
- R&D expenses for the six months ended June 30, 2024 amounted to
, compared to$2,788 thousand for the six months ended June 30, 2023. The decrease was primarily due to a reduction in salaries and reduced use of subcontractors.$3,449 thousand - Marketing, general and administrative expenses for the six months ended June 30, 2024 amounted to
, compared to$1,003 thousands for the six months ended June 30, 2023. The decrease was primarily due to a reduction in salaries, share-based compensation and professional services.$2,332 thousands - Financial expenses for the six months ended June 30, 2024 amounted to
compared to$526 thousand for the six months ended June 30, 2023.$1,496 thousand - Net loss for the six months ended June 30, 2024 was
compared to net loss of$4,481 thousand for the six months ended June 30, 2023.$7,277 thousand
As of June 30, 2024, the Company had cash and cash equivalents and short-term deposits of
BALANCE SHEETS | ||||||||
June 30, | December 31, | |||||||
2024 | 2023 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 3,076 | $ | 4,870 | ||||
Restricted cash | 138 | 140 | ||||||
Trade receivables | 119 | - | ||||||
Prepaid expenses and other receivables | 324 | 437 | ||||||
Total current assets | 3,657 | 5,447 | ||||||
NON-CURRENT ASSETS: | ||||||||
Property, plant and equipment, net | 10,180 | 10,825 | ||||||
Operating lease right-of-use assets | 1,014 | 1,200 | ||||||
Total non-current assets | 11,194 | 12,025 | ||||||
Total assets | $ | 14,851 | $ | 17,472 | ||||
The accompanying notes are an integral part of the financial statements.
|
BALANCE SHEETS | ||||||||
| ||||||||
June 30, | December 31, | |||||||
2024 | 2023 | |||||||
LIABILITIES NET OF CAPITAL DEFICIENCY | ||||||||
CURRENT LIABILITIES: | ||||||||
Trade payables | $ | 658 | $ | 535 | ||||
Operating lease liabilities | 364 | 396 | ||||||
Other payables | 650 | 849 | ||||||
Total current liabilities | 1,672 | 1,780 | ||||||
NON-CURRENT LIABILITIES: | ||||||||
Warrants liability | 3 | 96 | ||||||
Loan from others | 19,820 | 19,368 | ||||||
Non-current operating lease liabilities | 640 | 797 | ||||||
Total non-current liabilities | 20,463 | 20,261 | ||||||
SHAREHOLDERS' DEFICIT: | ||||||||
Ordinary shares of no par value: Authorized: 20,000,000,000 shares at June 30, 2024 and at December 31, 2023; Issued and outstanding 3,349,431,584 shares at June 30, 2024 and 1,857,169,984 shares at December 31, 2023 | - | - | ||||||
Additional paid-in capital | 121,272 | 119,506 | ||||||
Accumulated deficit | (126,816) | (122,335) | ||||||
Accumulated other comprehensive loss | (1,740) | (1,740) | ||||||
Total shareholders' deficit | (7,284) | (4,569) | ||||||
Total liabilities and shareholders' deficit | $ | 14,851 | $ | 17,472 | ||||
The accompanying notes are an integral part of the financial statements. |
STATEMENTS OF OPERATIONS | |||||||||||
For the six months ended June 30 | |||||||||||
2024 | 2023 | ||||||||||
Revenues | $ | 284 | $ | - | |||||||
Cost of revenues | 448 | - | |||||||||
Gross loss | (164) | - | |||||||||
Research and development expenses, net | $ | 2,788 | $ | 3,449 | |||||||
Marketing, general, and administrative expenses | 1,003 | 2,332 | |||||||||
Total operating expenses | 3,791 | 5,781 | |||||||||
Total operating loss | 3,955 | 5,781 | |||||||||
Total Financial Expenses net, | 526 | 1,496 | |||||||||
Net loss | $ | 4,481 | $ | 7,277 | |||||||
Net loss per share attributable to ordinary shareholders, basic and diluted | (0.002) | (0.006) | |||||||||
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted | 2,288,278,248 | 1,322,019,241 | |||||||||
The accompanying notes are an integral part of the financial statements.
|
STATEMENTS OF COMPREHENSIVE LOSS | ||||||||||
| ||||||||||
For the six months ended June 30 | ||||||||||
2024 | 2023 | |||||||||
Net loss | $ | 4,481 | $ | 7,277 | ||||||
Other comprehensive income: | ||||||||||
Foreign currency translation adjustments | - | (267) | ||||||||
Total comprehensive loss | 4,481 | $ | 7,010 | |||||||
The accompanying notes are an integral part of the financial statements.
|
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | ||||||||||||||||||||||||||||||
Ordinary shares | Additional paid-in | Accumulated comprehensive | Accumulated | Total shareholders' | ||||||||||||||||||||||||||
Number | Amount | capital | loss | deficit | equity | |||||||||||||||||||||||||
Balance as of January 1, 2024 | 1,857,169,984 | $ | - | $ | 119,506 | $ | (122,335) | $ | (4,569) | |||||||||||||||||||||
Issuance and exercise of warrants, net of issuance costs of | 1,491,240,800 | - | 1,433 | - | - | 1,433 | ||||||||||||||||||||||||
Vested RSU's | 1,020,800 | - | - | - | - | - | ||||||||||||||||||||||||
Share-based compensation | - | - | 333 | - | - | 333 | ||||||||||||||||||||||||
Net loss | - | - | - | - | (4,481) | (4,481) | ||||||||||||||||||||||||
Balance as of June 30, 2024 | 3,349,431,584 | - | $ | 121,272 | $ | (126,816 | ( | $ | (7,284) | |||||||||||||||||||||
Ordinary shares | Additional paid-in | Accumulated comprehensive | Accumulated | Total shareholders' | ||||||||||||||||||||
Number | Amount | capital | loss | deficit | equity | |||||||||||||||||||
Balance as of January 1, 2023 | 989,290,784 | $ | - | $ | 116,082 | $ | (115,835) | $ | (1,760) | |||||||||||||||
Exercise of warrants | 464,015,200 | - | 801 | - | - | 801 | ||||||||||||||||||
Vested RSU's | 664,800 | - | - | - | - | - | ||||||||||||||||||
Reclassification of warrants liability to equity | - | - | 398 | - | - | 398 | ||||||||||||||||||
Share-based compensation | - | - | 459 | - | - | 459 | ||||||||||||||||||
Other comprehensive income | - | - | - | 267 | - | 267 | ||||||||||||||||||
Net loss | - | - | - | - | (7,277) | (7,277) | ||||||||||||||||||
Balance as of June 30, 2023 | 1,453,970,784 | - | $ | 117,740 | $ | (123,112 | ( | $ | (7,112) |
STATEMENTS OF CASH FLOWS | |||||||||
For the six months ended June 30, | |||||||||
2024 | 2023 | ||||||||
Cash flows from operating activities: | |||||||||
Net loss | $ | (4,481) | $ | (7,277) | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation of property, plant and equipment | 652 | 285 | |||||||
Financial expense related to loan from others | 451 | 4,321 | |||||||
Revaluation of warrants | (93) | (3,333) | |||||||
Share-based compensation | 333 | 452 | |||||||
Decrease (increase) in receivables | (119) | - | |||||||
Decrease (increase) in other receivables | 110 | 8 | |||||||
Changes in operating lease right-of-use assets | 189 | (16) | |||||||
Increase in trade payables | 125 | (31) | |||||||
Changes in operating lease liabilities | (189) | 3 | |||||||
Increase (decrease) in other payables | (199) | (347) | |||||||
Net cash used in operating activities | (3,221) | (5,935) | |||||||
Cash flows from investing activities: | |||||||||
Purchase of property, plant and equipment | (8) | (383) | |||||||
Net cash used in investing activities | $ | (8) | $ | (383) | |||||
The accompanying notes are an integral part of the financial statements. |
STATEMENTS OF CASH FLOWS | ||||||||||
For the six months ended June 30, | ||||||||||
2024 | 2023 | |||||||||
Cash flows from financing activities: | ||||||||||
Proceed from exercise of warrants, net | $ | 1,433 | - | |||||||
Net cash provided by financing activities | 1,433 | - | ||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 121 | (265) | ||||||||
Increase (decrease) in cash, cash equivalents and restricted cash | (1,917) | (6,583) | ||||||||
Cash, cash equivalents and restricted cash at beginning of year | 5,010 | 14,215 | ||||||||
Cash, cash equivalents and restricted cash at end of year | $ | 3,214 | $ | 7,632 | ||||||
Supplementary disclosure of cash flows activities: | ||||||||||
(1) Cash paid during the year for: | ||||||||||
Interest | $ | 143 | $ | 725 | ||||||
(2) Non-cash transactions: | ||||||||||
Reclassification of warrants liability to equity | - | 398 | ||||||||
Exercise of warrants liability into shares | $ | - | $ | 801 | ||||||
Reconciliation of cash, cash equivalents and restricted cash: | ||||||||||
Cash and cash equivalents | $ | 3,076 | $ | 7,506 | ||||||
Restricted cash | 138 | 126 | ||||||||
Cash, cash equivalents and restricted cash | $ | 3,214 | $ | 7,632 | ||||||
The accompanying notes are an integral part of the financial statements. |
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.
Company website: www.scinai.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the closing of the transaction with EIB, ability of the Company to regain and remain compliant with the continued listing standards of Nasdaq, the potential of Scinai's NanoAb program, expected revenues of Scinai's CDMO business and timing of pre-clinical and clinical studies of the Company's anti-IL NanoAbs for the treatment of plaque psoriasis and their results. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; risk associated with the closing of the transaction with EIB; the risk that the Company will otherwise be unable to regain compliance and remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2024 and thereafter; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Photo: https://mma.prnewswire.com/media/2482084/Scinai_Immunotherapeutics.jpg
Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-publishes-q2-2024-financial-results-and-provides-business-update-restructures-29-million-bank-loan-to-equity-on-track-to-regain-nasdaq-compliance-by-august-23-302223463.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
What is the status of Scinai's (SCNI) Nasdaq compliance?
What are Scinai's (SCNI) Q2 2024 financial results?
What progress has Scinai (SCNI) made in its NanoAb development for psoriasis treatment?